THE TAPE

Alkermes Inc. plc

$46.53▼ −1.06%
Last close
Relative strength
78RS
of 99, against every stock▲ +20 on the month
Powering up
Developing
+12.7%
six months against Pharmaceutical Preparations
52-week range
−16.4%
from the high
$27.00$55.67
Setup
falling wedgefresh breakout
+4.3%
against the pivot at $44.59
No report date on the calendar.
Growth REALProof SHOWN
Quarter to Sep 30, revenue +22% on a year ago
11/16 O 47.02 H 47.76 L 46.26 Vol 1.1M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS78
vs pivot+4.35%
Tightening0.92×
Dry-up0.93×
Up/down vol0.04
From high16%
failed pokefresh breakout5 of 9checks
Powering up
Support and resistance
Support below
$44.69
-4.0% · tested 7× · last 2 sessions ago
Resistance above
$47.96
+3.1% · tested 8× · last 2 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 12.2 weeks and fell 24% from its ceiling at its deepest. The pivot is $44.59, and the stock closed 4.3% above that pivot. Its relative strength rating is 78.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+8.1%
Three months against its industry
+8.7%
Six months against its industry
+12.7%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 7.2% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$1.8B
+21.8% year on year
Operating margin
3.7%
Net margin
0.0%
Free cash flow
$227.4M
2.9% of market cap
Price to sales
4.45×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 3
Key takeaway
Growth with the cash to show for it: the quarter confirms the thesis.
Revenue
$480.1M
-3.2% QoQ · +21.8% YoY
Gross margin
—
Net income
$16.3M
Positive
Free cash flow
$90.1M
Cash generating

What the numbers say

  • Good: Revenue +21.8% year over year, -3.2% on the quarter
  • Good: Profitable: net income $16M, operating margin 7.5%
  • Good: Cash generating: operating cash flow $93M, free cash flow $90M
  • Net debt $866M · cash $631M
Revenue by quarter
Free cash flow
Net income
shares +4.7% in a year · net debt $866.4M

What is not obvious

  • Weak: Interest $28M takes 76% of operating income $36M
Final read
Growth: REAL · Economic proof: SHOWN
Key question: Does the next quarter repeat this one?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Entered a material agreementFiling · 2026-11-13
1.01
No measurable effect: stocks behave like random ones over the next three sessions (866 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-13
above 20d & 50d on 1.7x volume at 46.98
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Reported resultsFiling · 2026-11-04
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-11-03
reports 2026-11-03 bmo
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Tightening after a sharp runTape · 2026-10-29
range halved after a +16% thrust, at 45.25
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
Earnings date movedEvent · 2026-10-22
2026-10-28 -> 2026-11-03
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Earnings date movedEvent · 2026-10-21
2026-10-26 -> 2026-10-28
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Earnings date movedEvent · 2026-10-20
2026-10-28 -> 2026-10-26
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
16
$5,659,314 total

Sold: Gaffin David Joseph, Hopkinson Craig C., Nichols Christian Todd, snyderman nancy lynn MD, Wright Christopher I, Parisi Samuel Joseph.

Not counted above: 27 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-03 Gaffin David Joseph · EVP, CLO, Alkermes, Inc.sell2,035$93,956
2026-10-08 Reed Joshua · SVP, Chief Financial Officeroption exercise9,164
2026-10-08 Reed Joshua · SVP, Chief Financial Officerwithheld for tax4,069$163,208
2026-10-02 Gaffin David Joseph · EVP, CLO, Alkermes, Inc.sell2,034$83,455
2026-09-03 Gaffin David Joseph · EVP, CLO, Alkermes, Inc.sell2,034$97,652
2026-09-01 Hopkinson Craig C. · EVP R&D, Chief Medical Officeroption exercise5,000$122,950
2026-09-01 Hopkinson Craig C. · EVP R&D, Chief Medical Officersell9,000$422,874
2026-08-17 Nichols Christian Todd · SVP, Chief Commercial Officersell6,912$339,967

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
falling wedge
Level · ceiling$44.59
Wrong below$38.56
Measured target · the shape's own height$48.63
Reward against risk0.7×
Lines closed · of the gap they started with10%
Through to the apex43%
Touches · swing points the lines are drawn through11 up · 11 down
Length12.2 weeks
triangle
Level · ceiling$46.14
Wrong below$43.07
Measured target · the shape's own height$50.17
Reward against risk1.3×
Lines closed · of the gap they started with34%
Through to the apex34%
Touches · swing points the lines are drawn through12 up · 11 down
Length12.2 weeks
What lines up

5 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy12
Hold4
Sell0
Strong sell1

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
19w · 30%

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Alkermes Inc. plc (ALKS) — The Tape